This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants who experienced Adverse Events (AEs)
Timeframe: From first dose through End of Study (up to ~28 days per participant)
Number of participants who experienced Serious Adverse Events (SAEs)
Timeframe: From first dose through End of Study (up to ~28 days per participant)
Number of participants who experienced Treatment-Related Adverse Avents (TRAEs)
Timeframe: From first dose through End of Study (up to ~28 days per participant)